| Detailed information |
|---|
| CancerLivER ID | 2587 |
| Biomarker | DAZAP2, SPINT1, LGALS9, CYBA, BAZ2A, PPT1, S100A13, LGALS9, PIM2, TGFB1 |
| Biomarker Name/Symbol (given in Publication) | DAZ associated protein 2 or DAZAP2, Serine protease inhibitor Kunitz type 1 or SPINT1, Galectin 9 or LGALS9, Cytochrome b-245 alpha polypeptide or CYBA, Bromodomain adjacent to zinc finger domain 2A or BAZ2A, Palmitoyl-protein thioesterase 1 or PPT1, S100 calcium binding protein A13 or S100A13, Galectin 9 or LGALS9, Pim 2 oncogene or PIM2, Transforming growth factor beta 1 or TGFB1 |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential prognostic marker for grade progression of HCC and associated invasion and with metastsis of HCC; but not validated on indepedent dataset |
| Experimental Condition | G2 (moderately differentiated) HCV-HCC v/s G2 (poorly differentiated) HCV-HCC; associated with invasion or metastsis |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in G3 compared with G2 (with Fisher ratio more than 1.3) |
| Level of significance | P < 0.005 |
| Source | Tissue |
| PMID | 15710396 |
| Type of Biomarker | Prognostic |
| Pathway | cell adhesion, cell growth regulation, immunomod- ulation, apoptosis, and metastasis. |
| Cohort | 76 HCC samples : 50 were sero- positive for HCV antibody (HCVAb) and seronegative for hepatitis B virus surface antigen (HBsAg) and among 50 (7G1 (well differentiated, 35 G2 (moderately differentiated) and 10 G3 (poorly differentiated); 26 were seronegative for HCVAb |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Hepatocellular carcinoma (HCC) samples with positive hepatitis C virus (HCV) serology (well (G1), moderately (G2), and poorly (G3) differentiated tumors) with and without HCV infection. |
| Year of Publication | 2005 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |